Alpha9 Oncology

Alpha9 Oncology is a clinical-stage biotechnology company developing next-generation radiopharmaceuticals for the treatment of solid tumors. The company leverages a proprietary platform to engineer radioligand therapies with optimized pharmacokinetics, aiming to improve tumor uptake while minimizing off-target toxicity. Their pipeline includes programs targeting well-validated markers such as MC1R and PSMA, as well as novel targets. Alpha9 is focused on expanding the reach of radiopharmaceuticals beyond traditional applications through systematic design and rigorous clinical validation. The company's approach combines expertise in peptide chemistry and radiochemistry to create differentiated therapeutic candidates.